Dichloroacetate (DCA)

Category: compound

A pyruvate dehydrogenase kinase inhibitor that reverses the Warburg effect in cancer cells by forcing mitochondrial oxidation over glycolysis.

Mechanism Detail

DCA inhibits pyruvate dehydrogenase kinase (PDK), reactivating pyruvate dehydrogenase and shifting metabolism from glycolysis to mitochondrial oxidative phosphorylation. This reversal of the Warburg effect restores mitochondrial apoptotic signaling in cancer cells, increases ROS production, and opens mitochondrial transition pores.

Clinical Status

Phase I/II trials for glioblastoma and other solid tumors. Peripheral neuropathy is the dose-limiting toxicity. Used off-label in some integrative oncology protocols.

Relevant Diseases

Relevant Therapies

Related Terms